EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Add‐On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin‐Treated Mice and Patients With Pulmonary Fibrosis

Jie Huang iD, Nana Liu, Yueyue Jin, Shuangyu Han, Lian Li, Yunze Du, Luqing Wei, Dongsheng Li, Yan Zhang, Yubao Wang, Jau-Shyong Hong, Wen Ning und 1 weitere

Respirology · 2025-08 · 30 (8) · 736-750

DOI: 10.1111/resp.70043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology, online erschienen am 13.04.2025. Verfasst von Jie Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Dextromethorphan, Pyridones, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Major Project of China, Tianjin Key Medical Discipline(Specialty) Construction Project, National Key Technology R&D Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Idiopathic pulmonary fibrosis is a progressive interstitial lung disease characterised by excessive activation of myofibroblasts. However, currently available antifibrotic drugs exhibit limited efficacy. The dysregulation of redox processes plays a significant role in the pathogenesis of idiopathic pulmonary fibrosis. Dextromethorphan (DM) is used in the treatment of various inflammation‐related diseases. This study aimed to investigate the effectiveness of the combination of DM and pirfenidone (PFD) in treating idiopathic pulmonary fibrosis in both animal models and humans.

Methods

In a bleomycin‐induced pulmonary fibrosis mouse model, the anti‐fibrotic effects of DM and/or PFD were assessed by evaluating fibrotic area, hydroxyproline levels, and fibrotic markers. In a transforming growth factor‐β1‐induced cell model, proliferation, migration, fibrosis markers, and oxidative stress were analysed to elucidate the mechanisms underlying the anti‐fibrotic actions of DM and/or PFD. Finally, the efficacy of DM combined with PFD in patients with pulmonary fibrosis was evaluated by comparing pulmonary imaging scores and pulmonary function before and after treatment in the PFD group and the PFD + DM group.

Results

We observed that even ultralow doses of DM, either alone or in combination with PFD, demonstrated substantial protective effects in mice. Notably, administration of DM or combined drugs at 2 weeks after bleomycin modelling still showed anti‐fibrotic effects. In vitro, DM monotherapy and combination therapy restored the redox balance by suppressing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4/reactive oxygen species production and upregulating superoxide dismutase, contributing to their anti‐fibrotic mechanisms. In the clinical study, add‐on DM improved PFD in mitigating pulmonary function decline and improving chest high‐resolution computed tomography imaging scores.

Conclusions

Ultralow doses of dextromethorphan significantly alleviate pulmonary fibrosis in bleomycin‐treated mice through restoring the redox balance. Add‐on DM improves the effects of PFD in both bleomycin‐treated mice and patients with pulmonary fibrosis. Trial Registration: ChiCTR2000037602 image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DextromethorphanPyridonesIdiopathic Pulmonary FibrosisAnimalsBleomycinMiceDrug Therapy, CombinationHumansMaleDisease Models, AnimalOxidative StressFemaleMice, Inbred C57BLLungMiddle AgedPulmonary FibrosisCell Proliferation

Stichwörter der Autor:innen

NADPH oxidasedextromethorphanidiopathic pulmonary fibrosisoxidative stresspirfenidonereactive oxygen species

Substanzen

DextromethorphanPyridonesBleomycinpirfenidone

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Tianjin Key Laboratory of Protein Sciences, Nankai University, Tianjin, China.
  • Department of Respiratory, Tianjin People's Hospital, Tianjin, China.
  • Department of Pulmonary and Critical Care Medicine, Tianjin Beichen Hospital, Tianjin, China.
  • Department of Respiratory and Critical Care Medicine, Tianjin Hospital of Integrated Traditional Chinese and Western Medicine Nankai Hospital, Tianjin, China.
  • Graduate School, Tianjin Medical University, Tianjin, China.

ORCID-Profile: Jie Huang

Förderung

  • National Science and Technology Major Project of China
  • Tianjin Key Medical Discipline(Specialty) Construction Project
  • National Key Technology R&D Program
  • National Natural Science Foundation of China

Zitieren

APA

Huang, J., Liu, N., Jin, Y., Han, S., Li, L., Du, Y., Wei, L., Li, D., Zhang, Y., Wang, Y., Hong, J. S., Ning, W., & Feng, J. (2025). Add‐On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin‐Treated Mice and Patients With Pulmonary Fibrosis. Respirology, 30(8), 736-750. https://doi.org/10.1111/resp.70043

Vancouver

Huang J, Liu N, Jin Y, Han S, Li L, Du Y, et al. Add‐On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin‐Treated Mice and Patients With Pulmonary Fibrosis. Respirology. 2025;30(8):736-750. doi:10.1111/resp.70043

BibTeX
@article{Huang2025,
  author = {Huang, Jie and Liu, Nana and Jin, Yueyue and Han, Shuangyu and Li, Lian and Du, Yunze and Wei, Luqing and Li, Dongsheng and Zhang, Yan and Wang, Yubao and Hong, Jau-Shyong and Ning, Wen and Feng, Jing},
  title = {Add‐On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin‐Treated Mice and Patients With Pulmonary Fibrosis},
  journal = {Respirology},
  year = {2025},
  volume = {30},
  number = {8},
  pages = {736--750},
  doi = {10.1111/resp.70043}
}
Kostenlos starten →